The approach of dual or tandem CAR has been pursued for hematopoietic cancers as well, and some constructs targeting CD19/20 or CD19/CD22 entered clinical trials in hematological malignancies [57]. Here, CD19 is linked to hematopoietic and lymphoid cell neoplasm.